University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, Manchester, M23 9QZ, UK.
Expert Rev Respir Med. 2012 Dec;6(6):581-8. doi: 10.1586/ers.12.61.
Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction. Long-acting bronchodilators improve lung function and relieve dyspnea. Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. Aclidinium bromide is delivered using the Genuair(®) device, which is an easy to use multidose dry powder inhaler. Aclidinium bromide is rapidly metabolized in the plasma, so there is low systemic exposure that minimizes the anticholinergic side effects. This new long-acting bronchodilator provides effective bronchodilation with minimal side effects.
慢性阻塞性肺疾病的特征是气流阻塞不可逆转。长效支气管扩张剂可改善肺功能并缓解呼吸困难。阿地溴铵是一种新型长效抗毒蕈碱支气管扩张剂；III 期临床试验表明，每天给药两次可改善肺功能、呼吸困难和健康相关生活质量。阿地溴铵采用 Genuair（®）装置给药，这是一种易于使用的多剂量干粉吸入器。阿地溴铵在血浆中迅速代谢，因此系统暴露量低，最大限度地减少了抗胆碱能副作用。这种新型长效支气管扩张剂可提供有效支气管扩张作用，副作用最小。
